BioSpace News Archive

FDA has exercised enforcement discretion in regard to the ExeGen®ATM MiniSwine model clearing it for commercial use as a research model.

Studies Conducted by MD Anderson Cancer Center Elucidate the Mechanisms by Which EP-100 Kills Ovarian Cancer Cells on Its Own and Synergistically in Combination with a Leading PARP Inhibitor

Acquisition launches women’s health focus on cancer and may lead to new diagnostic options for ovarian cancer

Clovis intends to offer, subject to market and other conditions, $200 million aggregate principal amount of its convertible senior notes due 2025 in an underwritten registered public offering.

FDA’s target action date for the ALKS 5461 NDA is Jan. 31, 2019.

Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition and regression in FLT3 AML model

- Update on Ongoing MGMT-unmethylated Clinical Trials to be Presented on Tuesday April 17, 2018 -

Preclinical Data Showcase New T Cell Engaging Platform (TriTAC™) and Lead Drugs, HPN424 and HPN536, Targeting Prostate Cancer and Other Solid Tumors

Meniscus surgery is one of the most common surgical procedures in the United States, with one million performed annually

Biological Dynamics, a molecular diagnostics company dedicated to improving global health outcomes by empowering global communities with low-cost, accessible cancer diagnostics, today announced that new data on the company’s novel technology (ACE) will be presented at the American Association for Cancer Research 2018 Annual Meeting, at McCormick Place Convention Center on April 13 – 18 in Chicago.